Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer

Trastuzumab-induced cardiotoxicity (TIC) is the primary adverse event that limits the use of trastuzumab in HER2-positive breast cancer patients. However, the incidence and risk factors of TIC in HER2-positive gastric cancer are not known. Therefore, we evaluated the incidence and predictive factors...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Soo Park, Ji, Youn, Jong-Chan, Shim, Chi Young, Hong, Geu-Ru, Lee, Choong-Kun, Kim, Jee Hyung, Park, Hyung Soon, Heo, Su Jin, Beom, Seung Hoon, Kim, Hyo Song, Rha, Sun Young, Chung, Hyun Cheol, Kang, Seok-Min, Jung, Minkyu
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5617468/
https://ncbi.nlm.nih.gov/pubmed/28977908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18700
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars